Do investigational MET inhibitors have potential for the treatment of gastric cancer?

Click to increase image sizeClick to decrease image size

Declaration of interest

I Chau has a position on the advisory board for Eli Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono and Five Prime Therapeutics. He has also received research funding from Eli Lilly, Janssen-Cilag, Sanofi Oncology and Merck-Serono and an honorarium from Eli Lilly. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

One reviewer has received honoraria from the following companies who are developing MET inhibitors: Genentech/Roche, Amgen, and Lilly. Peer reviewers on this manuscript have no other relevant financial or other relationships to disclose.

Additional information

Funding

This work was funded by the National Institute for Health Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research.